Biotech6 hours ago
Novartis Acquires Avidity Biosciences for $12 Billion to Advance RNA-Based Therapies
Novartis will acquire U.S.-based Avidity Biosciences for $12 billion, expanding into advanced RNA-based therapies. The $72-per-share tender offer, a 46% premium, was unanimously approved. Avidity will...